Thetis Pharmaceuticals Receives Funding from the Crohn's & Colitis Foundation to Support Investigational Mucosal Healing Therapy for Inflammatory Bowel Disease

Crohn&39;s & Colitis Foundation&39;s IBD Ventures award supports development of Thetis&39; novel firstinclass Resolvin oral therapy TP317 for treatment of ulcerative colitis and Crohn&39;s diseaseBRANFORD CT ACCESSWIRE November 19...